Concerns Over Changes to Childhood Vaccine Policies After CDC Leadership Shakeup

Public health experts are preparing for potential shifts in childhood vaccine policies that might diverge from established scientific guidance. This comes as the Centers for Disease Control and Prevention (CDC) faces a significant leadership change.

Recently, health secretary Robert F. Kennedy Jr. dismissed CDC director Susan Monarez after she declined his request to endorse all suggestions from the agency’s vaccine advisory committee, which he had personally selected. Kennedy, known for his long-standing opposition to vaccines, has since appointed his ally, former biotech investor Jim O’Neill, as the acting director.

In addition to Monarez, four other senior CDC leaders—including the head of the National Center for Immunization and Respiratory Diseases—have also resigned.

Given this turmoil, experts are worried that the Advisory Committee on Immunization Practices (ACIP), set to convene on September 18-19, might propose major alterations that could restrict widely used vaccines. This meeting isn’t just about Covid-19 vaccines; the agenda includes discussions on vaccines for hepatitis B, respiratory syncytial virus, measles, mumps, rubella, and varicella.

During ACIP’s last gathering, the newly appointed members expressed some skepticism regarding vaccines but ultimately didn’t make any substantial changes to the existing immunization schedule. However, with Monarez no longer in charge, experts believe that committee members might feel more empowered to push for drastic changes. Jose Romero, a former chair of the committee with consulting ties to pharmaceutical companies, indicated that the environment at the upcoming meeting might shift dramatically.

It remains uncertain how long O’Neill will serve as acting director and how he will interact with ACIP’s recommendations. He has publicly stated his strong support for vaccines, yet his close ties to Kennedy raise eyebrows.

Kennedy and others in his administration have suggested that ACIP has traditionally rubber-stamped vaccine recommendations, even though the committee has, in some instances, critically debated evidence. They argue that vaccine manufacturers should face intensified scrutiny.

The recommendations from ACIP carry significant weight, influencing federal and private payers to cover vaccines deemed necessary, thus ensuring that they are available at no cost if approved by the CDC. This committee also decides which vaccines are included in the Vaccines For Children Program, which aids uninsured children or those on Medicaid—over half of American children receive vaccines through this program.

Particularly alarming to experts is the potential for the committee to modify or withdraw its prior endorsement of a preventive monoclonal antibody for infants against RSV. Additionally, members may reconsider the hepatitis B vaccine given to newborns—a shot that has historically prevented serious, chronic conditions.

Jason Schwartz, a public health professor at Yale, predicts a trend of the committee emphasizing alleged vaccine risks while downplaying their effectiveness. This shift could undermine decades of vaccine infrastructure.

Covid-19 Vaccine Updates

Last week, the FDA revoked emergency use authorizations for Covid-19 vaccines while issuing more restrictive approvals, impacting accessibility for young children. Pfizer’s vaccine, previously available to those over six months, is now limited to those older than five. Moderna’s vaccine remains accessible only to children six months and older if they have underlying health conditions putting them at risk.

Administration officials argue that while access to Covid vaccines persists, the risks associated with them may surpass their benefits, especially five years post-pandemic.

Experts anticipate that ACIP will align with the FDA’s new authorizations, which the American Academy of Pediatrics has called “deeply troubling.” The pediatric organization has released its own guidelines recommending that all children six months to 23 months should have access to Covid vaccines, along with those over two deemed at risk for severe illness.

RSV Vaccination Concerns

At the previous ACIP meeting, members voted to recommend Merck’s new monoclonal antibody for RSV, named Enflonsia. However, some members raised concerns, citing higher death rates in clinical trials among children receiving the antibody compared to those in the placebo groups. Despite the CDC and FDA defending the trial results, one committee member voted against the antibody, citing safety uncertainties.

There are suggestions that the committee might withdraw its support for both Merck’s and the Sanofi and AstraZeneca RSV antibodies, putting vulnerable infants at further risk. These antibodies have been crucial tools in protecting infants from severe RSV infections, which can lead to hospitalizations.

Romero expressed concern that a reversal on these antibodies would significantly jeopardize children’s health, noting that the measures have effectively reduced RSV hospitalizations in recent winters.

Hepatitis B Vaccine Under Fire

There are worries that ACIP might reevaluate the recommendation for the hepatitis B vaccine given to newborns. The committee chair previously questioned the necessity of administering this vaccine to every infant before discharge from the hospital, which has historically been a safety measure.

Experts argue that although mothers are tested for hepatitis B during pregnancy, it’s not always foolproof, and the implications of missing an infection can be severe for the child. The birth vaccine serves as a crucial safety net, and many fear that withdrawing it would undo progress in reducing hepatitis B cases.

MMRV Vaccination Challenges

A concern has also been raised about the MMRV vaccine. The first dose, administered to children aged 12 to 47 months, appears to carry a greater risk of seizures compared to separate MMR and varicella shots. The committee’s preference already leans toward administering these vaccines separately, so formally withdrawing support for the combination shot may not change practical application significantly.

However, concerns were voiced about how a shift in recommendations regarding seizure risks could be communicated. Misrepresenting this nuanced issue risks further complicating vaccination efforts amid growing measles outbreaks.